Novel coronavirus

According to separate studies, blood type does not affect susceptibility to Covid-19 in U.S. patients and an inhaled steroid commonly used to treat asthma can help keep patients with mild Covid-19 from getting sicker.

The U.S. Food and Drug Administration approved a prefilled syringe for self-injection of the allergic diseases treatment Xolair developed by Novartis and Genentech, a Roche company.

Treating Covid-19 patients at home with a commonly used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on April 12 which doctors said could change the way the disease is treated around the world.

AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.

Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.

AstraZeneca and Amgen said their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients’ dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.

Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of the potential first-in-class human monoclonal antibody tezepelumab hit the primary endpoint in severe asthma.

In a Phase III study, the biologic Dupixent met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.

AstraZeneca Plc said the company’s asthma treatment Fasenra for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.

The U.S. Food and Drug Administration approved a new indication for GlaxoSmithKline plc and Innoviva Inc.’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to the product’s current license for use in patients with chronic obstructive pulmonary disease (COPD).